SB477
Senate · 2026 sessionRepublicanInterim study340B drug program transparency
AIEstablishes reporting requirements for the department of health and human services, hospitals, and other entities participating in the 340B Drug Pricing Program and directs the department to require claim-level identifiers and exclusion rules to prevent duplicate discounts.
relative to increasing transparency in the 340B Drug Pricing Program.
Public and Mental HealthState GovernmentWelfare/Medicare/Medicaid
Status
Referred to interim study (Senate) · March 5, 2026- ✓Introduced
- ✕Senate
- House
- Governor
- Law
Division of testimony
0 submissionsSupport 0Oppose 0Neutral 0
No testimony matches these filters. Clear the search or set position to All.